Table 3 Crude and multivariable-adjusted ORs and 95 % CIs for the presence of carotid wall thickening according to quartiles of glycemic measures in subjects with glucose intolerance

HbA_1c, % (mmol/mol)

Q1, <5.4 (36)

99/243

1.00 (reference)

<0.001

1.00 (reference)

<0.001

Q2, 5.4–5.6 (36–38)

107/271

0.95 (0.67 to 1.35)

0.77

0.94 (0.64 to 1.37)

0.73

Q3, 5.7–6.2 (39–44)

168/326

1.55 (1.11 to 2.16)

0.01

1.32 (0.91 to 1.92)

0.15

Q4, ≥6.3 (45)

156/259

2.20 (1.54 to 3.15)

<0.001

1.96 (1.32 to 2.93)

<0.001

GA, %

Q1, <14.3

102/273

1.00 (reference)

<0.001

1.00 (reference)

<0.001

Q2, 14.3–15.3

114/272

1.21 (0.86 to 1.71)

0.28

1.23 (0.84 to 1.79)

0.29

Q3, 15.4–17.1

146/279

1.84 (1.31 to 2.58)

<0.001

1.68 (1.15 to 2.45)

0.007

Q4, ≥17.2

168/275

2.63 (1.87 to 3.72)

<0.001

2.12 (1.45 to 3.10)

<0.001

1,5-AG, μg/mL

Q1, <11.0

158/277

1.47 (1.05 to 2.06)

0.02

0.03

1.43 (0.99 to 2.07)

0.05

0.09

Q2, 11.0–16.9

120/273

0.87 (0.62 to 1.22)

0.41

0.87 (0.60 to 1.26)

0.47

Q3, 17.0–22.9

121/273

0.88 (0.63 to 1.23)

0.46

0.97 (0.67 to 1.41)

0.88

Q4, ≥23.0

131/276

1.00 (reference)

1.00 (reference)

FPG, mmol/L

Q1, <5.7

121/285

1.00 (reference)

<0.001

1.00 (reference)

<0.001

Q2, 5.7–6.1

120/279

1.02 (0.73 to 1.43)

0.89

0.86 (0.59 to 1.23)

0.40

Q3, 6.2–6.8

123/258

1.24 (0.88 to 1.73)

0.22

1.26 (0.87 to 1.82)

0.23

Q4, ≥6.9

166/277

2.03 (1.45 to 2.84)

<0.001

1.76 (1.21 to 2.56)

0.003

2-hour PG, mmol/L

Q1, <8.0

119/286

1.00 (reference)

<0.001

1.00 (reference)

0.14

Q2, 8.0–9.1

123/264

1.22 (0.87 to 1.72)

0.24

1.04 (0.72 to 1.50)

0.85

Q3, 9.2–12.3

125/273

1.19 (0.85 to 1.66)

0.32

0.92 (0.64 to 1.32)

0.64

Q4, ≥12.4

163/276

2.02 (1.45 to 2.83)

<0.001

1.41 (0.97 to 2.04)

0.07